A new study from China led by Dr. Cao Bin et al confirms what Dr. Peluso et al found earlier, as well as what the NIH director mentioned during her interview, about viral persistence.
TLDR:
- SA55 (nasal spray version) has ~80% effectiveness against symptomatic Omicron infection, with a price tag of ~$7 a week.
- Good safety profile as shown by 200K users.
- Now in phase-3 trial. 1/n bilibili.com/video/BV1294y1…
- SA55 (injectable mAB version) provides long protection (~180 days) for those immunocompromised unvaccinated participants.
- Already used as treatment for ~2000 immunocompromised elderly in December 2022 in Beijing against BF.7.14, and was very effective.
- Also in phase-3. 2/n
- They're also collaborating with Moderna and other vax companies to develop new vaccines based on DMS predictions.
- In a retrospective analysis they're able to make WT vaccine by Apr 2020, or BA.5 vaccine by Sept 2022, using the DMS prediction approach. 3/n